Pharmacotherapy of Insomnia

Journal of Central Nervous System Disease

Review

Jaime M Monti¹  David N Neubauer²  David Warren Spence³  Kenneth Buttoo⁴  Seithikurippu R Pandi-Perumal⁵ 

[1] Department of Pharmacology and Therapeutics, School of Medicine Clinics Hospital, University of the Republic, Montevideo, Uruguay.;Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University, Baltimore, MD, USA;Independent Researcher, Toronto, ON, Canada;Pickering, Whitby and Bowmanville Centre For Sleep Disorders, Pickering, ON, Canada;Somnogen Canada Inc., Toronto, ON, Canada;

关键词: benzodiazepine;    drugs;    hypnotics;    insomnia;    medication;    sleep;   

DOI  :  10.1177/1179573518770672

 received in 2016-10-17, accepted in 2018-03-22,  发布年份 2018

来源: Sage Journals

【 摘 要 】

Insomnia remains a common clinical concern that is associated with negative daytime consequences for patients and represents a significant public health problem for our society. Although a variety of therapies may be employed to treat insomnia, the use of medications has been a dominant approach. Regulatory agencies have now classified insomnia medications into 4 distinct pharmacodynamics classes. Medications with indications approved for insomnia treatment include benzodiazepine receptor agonists, a melatonin receptor agonist, a selective histamine receptor antagonist, and a dual orexin/hypocretin receptor antagonist. Both pharmacodynamic and pharmacokinetic advances with hypnotic medications in recent years have expanded the pharmacopoeia to allow personalized treatment approaches for different patient populations and individual sleep disturbance patterns.

【 授权许可】

CC BY-NC   
© The Author(s) 2018

【 图 表 】

Figure 3.

Figure 1.